AbbVie Is Maintained at Overweight by Morgan Stanley

Dow Jones13:40 ET

Botox Innovator Revance Therapeutics Goes Private In Over $900M Deal

BenzingaAug 12 11:50 ET

Correction to Big Drugmakers Are Clinching Smaller Deals Article -- WSJ

WSJAug 12 10:30 ET

Express News | Abbvie Inc. : Morgan Stanley Raises Target Price to $218.00 From $211.00

ReutersAug 12 09:53 ET

Morgan Stanley Adjusts Price Target on AbbVie to $218 From $211, Maintains Overweight Rating

MT NewswiresAug 12 06:48 ET · Ratings

The Yen Carry Trade Is a Distraction. Stocks Have More Fundamental Problems, Says Morgan Stanley's Wilson

MarketWatchAug 12 06:22 ET